MedTrace Logo

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

NCT01497119 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2015-12-02

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-39758979 in adult Japanese patients with moderate, active atopic dermatitis.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

JNJ-39758979, 300 mg

Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.

DRUG

JNJ-39758979, 100 mg

Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.

DRUG

Placebo

Form=tablet, route=oral use, once daily for 6 weeks.

Sponsors & Collaborators

  • Janssen Pharmaceutical K.K.

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutical K.K., Japan Clinical Trial · Janssen Pharmaceutical K.K.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01497119 on ClinicalTrials.gov